Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | LSS | P48449 | 2/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | BCL9 | O00512 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17080654 | 0.90 | MGLL (0.76) | MGLLKCNH2GAAFAAHLSS | |
| SCHEMBL12916726 | 0.86 | MGLL (0.76) | MGLLGAAFAAHTRPV1BCL9 | |
| SCHEMBL18712660 | 0.80 | MGLL (0.70) | MGLLGAAFAAHTRPV1BCL9 | |
| SCHEMBL18291923 | 0.80 | MGLL (0.51) | MGLLKCNH2GAAPOLBHTT | |
| SCHEMBL11668314 | 0.79 | MGLL (0.86) | MGLLGAAFAAHTRPV1BCL9 | |
| SCHEMBL14565135 | 0.79 | MGLL (0.86) | MGLLGAAFAAHTRPV1BCL9 | |
| SCHEMBL19412173 | 0.78 | MGLL (0.84) | MGLLGAAFAAHTRPV1BCL9 | |
| SCHEMBL18703462 | 0.78 | MGLL (0.78) | MGLLGAAFAAHTRPV1BCL9 | |
| SCHEMBL1400533 | 0.76 | MGLL (1.00) | MGLLBCL9CTNNB1 | |
| SCHEMBL16139295 | 0.76 | MGLL (1.00) | MGLLHTTFAAHTRPV1BCL9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11141489-B2 | Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid | SANOFI (FR) | 2021-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11141489-B2 | Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid | GLP1R, GIPR, GCGR | MGLL 413/4885KCNH2 2872/4885GAA 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.